SUZHOU INDUSTRIAL PARK, March 8, 2018 – Suzhou SmartNuclide Biopharmaceutical Co., Ltd. (SmartNuclide), a biopharmaceutical company focused on discovering and developing innovative radiopharmaceuticals, today announced that the company secured its Series Pre-A investment round led by Beijing-based Waston Capital, joined by Zhuhai-based Longmen Capital and Suzhou-based Kongton Capital. The proceeds will allow SmartNuclide to run a phase 1/2 trial with its first clinical program, rhTSH, which is expected to received its IND clearance very soon, as well as further pre-clinical testing for its first radiotracer for whole-body PD-L1 expression imaging.